184 related articles for article (PubMed ID: 21986854)
1. Unilateral hearing loss due to pegylated interferon-α2b and ribavirin therapy.
Jain S; Midha V; Sood A
Indian J Gastroenterol; 2011 Sep; 30(5):239-40. PubMed ID: 21986854
[No Abstract] [Full Text] [Related]
2. Pegylated interferon/ribavirin-induced sudden sensorineural hearing loss in a patient with chronic hepatitis C.
Atug O; Akin H; Yilmaz Y; Sari M; Tozun N
J Gastrointestin Liver Dis; 2009 Jun; 18(2):256. PubMed ID: 19565068
[No Abstract] [Full Text] [Related]
3. Autoimmune thrombocytopenia induced by PEG-IFN-alpha2b plus ribavirin in hepatitis C.
Sagir A; Wettstein M; Heintges T; Häussinger D
Dig Dis Sci; 2002 Mar; 47(3):562-3. PubMed ID: 11911342
[No Abstract] [Full Text] [Related]
4. [Autoimmune hemolytic anemia in a case of chronic hepatitis type C 56 weeks after initiation of second line treatment with pegylated interferon alpha2b/ribavirin combination therapy].
Nishino R; Ikeda N; Unoura M
Nihon Shokakibyo Gakkai Zasshi; 2011 Sep; 108(9):1571-8. PubMed ID: 21891998
[TBL] [Abstract][Full Text] [Related]
5. [Side effects of interferon-based therapy for chronic hepatitis C virus infection and clinical management of them].
Iwasaki Y; Ikeda F; Yamamoto K
Nihon Rinsho; 2011 May; 69 Suppl 4():215-20. PubMed ID: 22096922
[No Abstract] [Full Text] [Related]
6. Managing adverse effects of interferon-alfa and ribavirin in combination therapy for HCV.
Slim J; Afridi MS
Infect Dis Clin North Am; 2012 Dec; 26(4):917-29. PubMed ID: 23083824
[TBL] [Abstract][Full Text] [Related]
7. Alopecia universalis as a side effect of pegylated interferon α-ribavirin combination therapy for hepatitis C: a rare case report.
Verma P; Dayal S; Jain VK; Amrani A
J Chemother; 2017 Dec; 29(6):380-382. PubMed ID: 27741937
[TBL] [Abstract][Full Text] [Related]
8. Summaries for patients. Pegylated interferon with or without ribavirin for patients with hepatitis C receiving hemodialysis.
Ann Intern Med; 2013 Dec; 159(11):I-14. PubMed ID: 24297207
[No Abstract] [Full Text] [Related]
9. [Pegylated intereferon hematological safety in comparison with standard].
Fazylov VKh; Manapova ÉR; Tkacheva SV; Sozinova IuM
Eksp Klin Gastroenterol; 2012; (6):96-9. PubMed ID: 23402198
[TBL] [Abstract][Full Text] [Related]
10. Side effects of therapy for chronic hepatitis C.
Russo MW; Fried MW
Gastroenterology; 2003 May; 124(6):1711-9. PubMed ID: 12761728
[No Abstract] [Full Text] [Related]
11. Severe autoimmune hemolytic anemia in a patient with chronic hepatitis C during treatment with Peg interferon alfa-2a and ribavirin.
Ennaifer R; Cheikh M; Romdhane H; Hefaiedh R; Ben Nejma H; Bel Hadj N
Tunis Med; 2014 Jan; 92(1):42-3. PubMed ID: 24879173
[No Abstract] [Full Text] [Related]
12. Summaries for patients. Duration and dose of antiviral treatment for chronic hepatitis C.
Ann Intern Med; 2004 Mar; 140(5):I67. PubMed ID: 14996694
[No Abstract] [Full Text] [Related]
13. Pegylated interferon, but not conventional interferon therapy induced severe skin lesions.
Li Z; Ji F; Zheng Y; An J; Peng Z
Ann Hepatol; 2012; 11(4):570-1. PubMed ID: 22700642
[No Abstract] [Full Text] [Related]
14. A chronic subdural hematoma in a patient receiving combination therapy with pegylated interferon alfa-2b and ribavirin for chronic hepatitis C.
Goto T; Ohshima S; Miura K; Shibuya T; Sato W; Dohmen T; Kamada K; Kanata R; Sakai T; Chiba M; Sugimoto Y; Minami S; Ohnishi H
Intern Med; 2013; 52(18):2057-60. PubMed ID: 24042512
[TBL] [Abstract][Full Text] [Related]
15. Retinal vein thrombosis associated with peginterferon alpha 2b plus ribavirin in a chronic hepatitis C patient.
Such Díaz A; Barrueco N; Esteban Alba C; Escobar Rodríguez I
Farm Hosp; 2011; 35(2):93-4. PubMed ID: 20615736
[No Abstract] [Full Text] [Related]
16. [Development of sarcoidosis during treatment for chronic hepatitis C with pegylated interferon alfa-2a and ribavirin: case report and literature review].
Cacopardo B; Pinzone MR; Nunnari G
Infez Med; 2013 Mar; 21(1):40-44. PubMed ID: 23524900
[TBL] [Abstract][Full Text] [Related]
17. Taste disturbances during therapy with pegylated interferon-alpha 2b and ribavirin in patients with chronic hepatitis C.
Klimacka-Nawrot E; Musialik J; Suchecka W; Petelenz M; Hartman M; Lichtański P; Błońska-Fajfrowska B
Wiad Lek; 2010; 63(4):289-99. PubMed ID: 21608370
[TBL] [Abstract][Full Text] [Related]
18. A case of irreversible leukoencephalopathy in a patient with C virus hepatitis treated with pegylated interferon-alpha-2b and ribavirin.
Iacob SA; Petrescu AM; Iacob DG
Rom J Intern Med; 2013; 51(3-4):197-200. PubMed ID: 24620633
[TBL] [Abstract][Full Text] [Related]
19. [Exceptional pancytopenia secondary to treatment with pegylated interferon and ribavirin].
Wikman Jorgensen PE; Jover Díaz FM; Cuadrado Pastor JM
Gastroenterol Hepatol; 2007 Apr; 30(4):253. PubMed ID: 17408558
[No Abstract] [Full Text] [Related]
20. Cost effectiveness of hepatitis C treatments: Need for a comprehensive evaluation.
DeNardo Z; Choi M; Stiller M; Buechel D
Kaohsiung J Med Sci; 2017 Nov; 33(11):584-585. PubMed ID: 29050677
[No Abstract] [Full Text] [Related]
[Next] [New Search]
